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Although theaflatoxinswerediscoveredmorethan30yearsag, thereisstillconsiderableconitoversysurroundingtheir
human healtheffectL Mostcountieshaveintduced lntocontrolthelevelofaflat I_sinfood, butitisnotknown
ifthesepernitted levelsstill poseas cocerrisk.Furthenore, itisunwiythatallthesourcesofhununaflatoin
exposurehavebeendiscovered, noriftheliveristheonly,orindeed,majortargetorganforaflatoxin-inducedcancerin
man. Inourlaboratorywehaveusedboth nmunologicalandHPLCmethodstoexaminehumanDNAfromavarietyof
tissuesandorganstoidentifyandquantifyaflatoxinDNA-adducts. WehavealreadydetectedaflatoxinB1 (AFB")-DNA
adductsinformalin-fixedtimuefromanaccutepoisoninginidentinSouthestAsia.Herewehave anedhuman colon
andrectumDNAfromnormal andtumoroustissueobtainedfromcancerpatientsandcolon,liver,pancreas, breast,and
cervixDNAfromautopsyspecimens.AFBI-DNAadductsweredetectedinalltissetypes a andrangedfrom0-60
adducts/10'nucleotides. Wheresamplesizealowed,theadductlevelswereconfirmedbyHELCanalysis. Tumortissues
tendedtohavehigheradductlevelsthannormaltissuefromthesameindividual,andlevelsgenerallyincreasedwithpa-
tient age. In samples analyzed by HPLC, the adducts present had the chromatographic properties of[8,9-dihydro-8-
(NW-formyl)-2, 5; 6'-triamino4'-o(o-pyramidyl-9hydrosy aflatn B1, thering-openedformoftheAB,-guanine
adduct. The levelofadductsobservedinindividuals fromtheUKwereofteninthe same rangeasthoseseenincitizens
ofThird-Wbrldcoumtries. AFB,-DNAadductvaluesinthisrange,iLe,11W,havebeenreportedtoresultinthedevelopment
oftumorsinratsandtroutsdosedwithAFB1.Thiswouldindicatethataflatdnsmayposeacarcinogenicrlsktoavariety
oforgansfortheUKpopulationandthatthereareeitherunknownsourcesofaflatoxininourdietorthatthepresentper-
mitted level in food is too high.
Introduction
Aflatoxins aretoxic secondary metabolites ofseveral species
ofthe Aspergillus molds, initially discovered as a result ofthe
death oflargenumbersofturkeys andtroutgivencontaminated
feed in the 1950s. Since then a wealth ofinformation has been
amassed as tothechemical structure, metabolism, mutagenici-
ty, andanimalcarcinogenicity oftheaflatoxinsand, inparticular,
the most potentanimal carcinogen, aflatoxin B1 (AFB1). How-
ever, thepossible roleofaflatoxins inhumancarcinogenicity is
still controversial (1). Epidemiological studies (2-7) have shown
a correlation between aflatoxin exposure and primary hepato-
cellular carcinoma (PHC) incidence in several Third-World
countries. These studies have been criticized for failing to take
into accountotherconfounding factorssuch aspossiblehepatitis
B infection or exposure to pyrrolizidine alkaloids, selenium
compounds, and alcohol (1,8). More recent studies have made
attempts to compensate forsuch factors, somestill finding arela-
tionshipbetweenAFB, exposureandPHCand somenot(9-11).
Suchstudiesillustratethatthemultifactorial nature ofhuman car-
cinogenesis makes it impossible to study the effect of a single
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compoundinisolation. Thesestudiesalsohighlighthowinsen-
sitiveepidemiologicalstudiesofthisnatureareandshowthatit
isinsufficienttobaseexposuredataonlyonanalysisoffood. The
analysis of tissue DNA adduct levels, serum albumin adduct
levels, and fecalandurinary aflatoxins shouldallbecombined
togive a morerealistic picture ofaflatoxin exposure.
DNA binding experiments, mutation assays, and RNA syn-
thesis inhibition tests have also indicated that aflatoxin me-
tabolism inmanismorelikethatseeninrefractoryspeciessuch
as the hamster than the susceptible rat (8). However, these
studieshaveonlyusedtissuesfromafewindividualsanddonot
ruleoutthepossibilitythatintheheterogeneous humanpopula-
tion some individuals may be more susceptible than others,
unlike an inbred species of rat. Also, a recent study on the
biotransformation ofAFB, by livermicrosomes fromavariety
of species, using much lower substrate concentrations more
representativeofrealexposurelevels, foundtheproportioncon-
vertedtoAFB,-8,9-epoxide (theultimatecarcinogen)increased
at lower substrate concentrations in the case ofrat and human
microsomes(12). Furthermore, riskestimatesoflivercancerdue
to aflatoxin exposure, extrapolated from animal and human
studies concludedthat, despitetheFischer ratbeing more sen-
sitive thanother species, riskestimates were all within a reas-
onable range and clearly within the same order ofmagnitude
regardless ofthe speciesused tobuildthe model (13).
Astudy intheUnitedStatescomparedliver, kidney, andcol-
on cancer data for Southeastern rural and urban areas, on the
assumptionthataflatoxinexposurewouldbehigherintheformerHARRISONAND GARNER
duetothehighconsumptionofcorngritsandthelocal consump-
tionofunmarketable peanuts. This study came totheconclusion
that there was no correlation between aflatoxin exposure and
cancer development (8). However, our previous findings (14;
Harrisonetal., inpreparation)ofaflatoxinadductedctoliverDNA
fromUKandFrenchresidents notknowntoconsumelarge quan-
titiesofeithergritsorpeanuts, indicatesthataflatoxin exposure
indevelopedcountries isprobably muchhigherthanpreviously
thought, thuscastingdoubts astothevalidityoftheurbancontrols
intheU.S. study. Therehave alsobeen anumberofclinical reports
ofhighlevelsofaflatoxins inanumberofpatientsincluding cancer
patientsfromnon-Third-W)rldcountries (15-20). Whilein no way
provingthataflatoxin causedthese cancers, these reportsdo sup-
portthehypothesis that aflatoxin exposure is notconfined tothe
Third World.
Recentnewsourcesofaflatoxin exposurehavebeenidentified
infigs, yogurt, sunflowerseeds, medicinal plantsandevenheroin.
These sources are to be added to the listofpreviously identified
sourcesofexposurenowbeing consumed in increasing amounts
indeveloped countries such as corn, rice, beans, nuts, and spices
(21-26). All the above commodities and other, as yet uniden-
tified, sources of aflatoxin exposure could therefore be con-
tributing to asubstantial aflatoxin burden in developed countries.
Many governments have therefore continued to class aflatox-
insasprobablehuman carcinogens (27), and 56 countries todate
have imposed regulations to attempt to limit human exposure
(28). The research therefore continues on a variety offronts to
establish what, if any, role aflatoxins play in human car-
cinogenesis. Ourselves and others (14,29,30; Harrison et al., in
preparation) have examined human tissues for the presence of
AFBI and its DNA adducts on the premise that this gives an in-
dicationofexposure and DNAdamagepotential. Other resear-
chers have developed methods to analyze aflatoxins or adduct
levels in a variety of body fluids, which would allow a much
larger number ofsamples over a time course to be investigated
than is possible by examining solid tissues (31-35). Such
methodologies, especially in conjunction with the current
hepatitis vaccination program, will allow the investigation ofthe
contribution of thesetwo possible culprits of human PHC in
Third-World countries and the potential role of aflatoxins in
cancer formation in developed countries.
AFBI is metabolised by liver microsomes to an 8-9 epoxide
that can bind to glutathione to produce a less toxic metabolite,
whichcanbetransported around thebody and excreted inthebile
(36). However, theepoxide is also capable ofbinding to cellular
proteins, RNA, and DNA. It is the binding ofAFB, to DNA,to
form DNA adducts (37), which has been related to tumor
development inanimals (38) and is believed to play a role in car-
cinogenesis. One possible mode of action of such adducts in
cancer development has been indicated in contemporary studies
ofthepS3 tumor-suppressor gene. Mutational hotspots havebeen
detected in the gene from human livers obtained from South
Africa where aflatoxin exposure is known to be high (39).
Here we report on the surprising finding ofaflatoxin adducted
toDNA fromavariety oftissues from UK residents who have not
previously been considered to be exposed to significant amounts
ofaflatoxin. Using an immunological system composed ofim-
munoaffinity chromatography purification and inhibition
ELISA, described previously (40), we have detected AFBI
bound to DNA in approximately 50% ofsamples analyzed from
a variety oforgans.
Adduct levels detected range from 0.03 to 60.5 adducts/106
nucleic acid bases, which represents up to tens ofthousands of
DNA adducts per cell. Similar levels ofadducts have been cor-
related with liver tumor development in a variety of animal
species (40).
Materials and Methods
DNA was purified from normal colon and rectum samples
obtainedduring surgery atYorkDistrict Hospital, predominantly
from colon cancer patients. "Normal" colon, breast, pancreas,
and liver samples wereobtained fromcadavers atautopsy at York
District Hospital and TheWhittington Hospital, London. Liver
autopsy samples from Africa and Southeast Asia were provided
by The Liverpool School ofTropical Medicine. All patient and
sample details available are recorded in Table 1.
All samples were extracted and purified using the method of
Gupta (41). Briefly, tissues were homogenized in 1% w/v SDS,
digested withproteinase K (Sigma, Dorset, UK), extracted se-
quentially with phenol, phenol: chloroform: isoamyl alcohol
(25:24:1) andchloroform: isoamyl alcohol (24:1), digested with
RNAse A and Ti (Sigma, Dorset, UK), and reextracted, as
above. Once purified, samples were incubated in 15 mM
Na2CO3/30 mM NaHCO3, pH 9, for 2 hr to convert any AFB,-DNA adducts present to the more stable imidazole ring
opened (IRO) form (42). Toenabletherecovery of <90% ofthe AFB,-DNA adducts present by immunoaffinity chroma-
tography (40), DNA was subjected toacid hydrolysis (0.1 N HCI
at70°C) for20min to release IROAFBI-guanine (43), and the
pH was readjusted to neutral.
To increase the sensitivity oftheAFB, adductanalysis and to
remove any interfering compounds, all samples were passed
through an immunoaffinity column containing an anti-AFB,
monoclonal antibody (Biocode Ltd, York, UK). Thecolumn was
prewashed with 15 mM NaCl/1.5 mM Na3C6H5O7 2H2O, pH
7.4, samples applied in the same buffer, and after further
washing, any bound material was eluted with 100% methanol.
Eluents were dried in a Univap centrifugal evaporator (Uni-
science, London, UK), resuspended in 10mM K2HPO4/150 mM
NaCl, andboiled to denature any antibody eluted from the col-
umns. Samples were quantified by comparison of inhibition
levels in an aflatoxin inhibition ELISA with those obtained for
a series ofAFB,-DNA standards prepared by peracid activation
ofAFB, (43). All samples were analyzed both neat and as 1/10
dilutions, in triplicate, on at least two separate occasions. Calf
thymus DNA was used as a negative control to account for any
nonspecific inhibition. We have previously established, using
DNA extracted from rats treated with [3H]AFB1, thatthis system
accurately quantifies adduct levels as confirmed by radioactivity
measurement (data not shown).
Where sample sizeallowed, acid hydrolyzed DNA (pH 3) was
analyzed by HPLC onan ODS2 C-18 25 x 0.3 cmreverse-phase
columnusingamethanol gradient from0-100% v/v over 30min
at1 mL/min, controlled by a Gilson Anachem HPLC system.
The column eluent was monitored at 362 nm UV and 470 nm
fluorescence (excitation 360nm). Thepeakareas andretention
times were compared to a series ofAFBI-DNA standards syn-
thesized by peracid activation, as above. Sample sizes of
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Table 1. Patientdetails.'
Patient Duke's
no. Tissue Type stage Age Sex
1 Rectum N - 80 F
I T C 80 F
2 N - - F
2 T - - F
3 N - 66 F
3 T B 66 F
4 N - - F
4 T - - F
5 N - - F
5 T - - F
6 T - - M
26 T B 82 F
27 N - 64 M
27 T B 64 M
7 Colon N - - M
8 N - - -
9 N - _ _
17 N B 71 M
18 N - 52 F
18 T C 52 F
19 N B 71 M
30 T A 71 F
32 T B 52 M
10 Sigmoid colon N - 84 M
10 T B 84 M
11 N - - M
11 T - - M
12 N - 74 F
13 N - - F
14 N - - M
15 N - - F
16 N B 75 F
20 T B 65 M
23 N C 60 F
24 N - 64 F
24 T B 64 F
21 Right colon T B 83 F
25 T B 66 F
29 T - 73 F
22 Transverse N - - F
28 Colon T C 59 M
31 Left colon T C 50 M
Ad,ducts/106
nucleotides
0
0.67
0.26
10.26
4.2
2.9
0
2.6
5.1
5.3
0
0
0
0
3.07
0.19
3.07
0.72
2.6
1.0
0.04
0
0
0
0
0
4.1
2.2
0.41
2.07
0.41
0
6.1
0
0
56.9
5.9
0
0
0
0
0
Ad
Patient
no. Tissue
L:B:C:12 Liver, breast,
cervix N
L:13 Liver N
L:14 Liver N
L:16 Liver N
L:P:23 Liver, pancreas N
L:C:26 Liver, cervix N
P:28 Pancreas N
B:31 Breast N
L:P:C:36 Liver, pancreas,
cervix N
L:P:39 Liver, pancreas N
P:40 Pancreas N
L:P:C45 Liver, pancreas,
cervix N
P:B:54 Pancreas, breast N
L:57 Liver N
L:P:59 Liver, pancreas N
L:P:B:60 Liver, pancreas,
breast N
B:70 Breast N
L:P:37 Liver, pancreas N
P:38 Pancreas N
L:56 Liver N
L:67 Liver N
P:72 Pancreas N
F Cervix N
414 Colon N
404 N
420 N
406 N
409 N
413 N
418 N
407 N
P1b Liver
P2
b
p3b
P6 b
Peb
P8
b
kutopsy samples
Duke's Adducts/106
pe stage Age Sex nucleotides
- 32 F 1.02, 3.36, 0.48
- 72 M 0
- 92 F 0
- 69 M 0
- 88 F 0,0
- 82 F 0.59,1.92
- 66 M 0.33
- 85 F 0
- 89 F 1.35,0.21,4.9
- 72 F 0, 0.33
- 76 M 0.29
- 66 F 0.23,0.34,0
- - F 0.47,0
- 72 F 0
_- F 0,0
- - F 0.43,0,0
- - F 0.43,0,0
- - F 0.35,0
- - M 0
- - F 0
- - M 1.29
~~~~0
- - F 0
- - - 0.62
- - - 0.24
- - - 0.17
~~~0
~~~0
~~~0
~~~0
~~~~~~1.8
~~~~~~19.8
~~~~~~1.5
~~~~0
~~~~0
~~~~~6.3
~~~0
aPatient details showing age, sex, tissue type (N, normal; T, tumor), Duke's classification (A, least invasive; D, most invasive), and AFB,-DNA adducts/106
nucleotides, giving an indication ofthe invasiveness oftumors at the time of surgery; (-) unknown.
cSamples were from Africa and Southeast Asia.
ibble2. Comparisonofthepercentageofsamplespositiveforthepresence (FAPY). Toestablishiftheimidazolering-openedformwasthe
ofAFB,-DNAadducts fromdifferenttissues. adductalready presentinthetissues, highly adducted samples
Numbersamples were analyzed immediately after DNA extraction and after e Numberof with AFB-DNA % ofpositive deliberateringopening byincubationinmildalkali. Tissue type samples analyzed present samples
Liver 46 30 64 Colona 26 14 54 Results
Control colon 10 4 40
Rectum 14 8 57 Utilizingaflatoxin immunoaffinitychromatographycombined
Pancreas 13 6 46 withinhibition ELISAquantification forAFB,-DNAadducts, Breast 5 2 40 wt niiinEIAqatfcto o F,DAadcs
Cervix 5 3 w0 wehavedetectedadductsinalltissuestypesexaminedtodate. Out
Total 119 67 56 of117samplesanalyzed,65haddetectablelevelsofAFBI-DNA
aFromcancerpatients. adducts,representingfrom40to65%ofallsamplestested,depen-
300-1000mgDNA werechromatographed andcomparedwith
standardsof100, 50, 10, 5 ng [8,9-dihydro-8-(N5-formyl)-2', 5',
6'-triamino-4'-oxo-(N5-pyramidyl)-9-hydroxyaflatoxin B,
dingontheorganexamined(Table2).Manyofthesamplesfrom
UKresidentshadadductlevelswithinthesameorderofmagnitude
as samples from Southeast Asia and Africa (samples P1-P8),
whereaflatoxin exposureisknowntobeendemic(Fig. 1).
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SamplesthatwereanalyzedbyHPLCdisplayedapredominant
retention peakat 16 min, identical tothatseenforthe synthetic
IRO AFB,-DNA (Fig. 2). Quantification ofAFBI-DNA ad-
ducts by thetwo methods gave comparable results (Table 3).
Comparison of HPLC peak retention times for samples
analyzed immediately after DNA extraction and after alkali
pretreatment indicate thattheadductspresent inthetissue were
already in the ring-opened form. As it is the ring-opened form
oftheadductthataccumulateswithchronicexposure(44), these
results indicate that the levels of adducts detected in the UK
residents aremorelikelytobeduetochronic aflatoxinexposure
thanacuteexposurepriortosampleanalysis. Wherenormal and
tumor tissue was available from the same patient, the adduct
levels in thetumortissuetended tobehigherthanthose seen in
the normal tissue (Fig. 3).
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FIGURE 2. (A) HPLC trace of acid hydrolyzed imidazole ring-opened
AFB,-DNA synthesized by peracidactivationofAFB1. (B) HPLC trace of
imidazole ring-opened acid-hydrolyzed human colon DNA. Colon DNA
samplesthathadnotbeendeliberately ringopenedby incubation inalkali also
gave themajor retention peak at 16 min. Full-scaledeflection = 0.1 absor-
bance units (FS) for UV and 0.01 relative fluorescence units (RFU) for
fluorescence detection.
0
BREAST CERVIX "E0XPOED"
LIVER
Table 3. Comparison of AFBI-DNA adduct values in human colon as
measured by competitive inhibitionELISAand HPLC.
Adducts/106 nucleotides
Sample no. ELISA HPLC
2 (Tumor) 10.60 20.30
12 2.20 2.20
14 2.20 2.20
14 2.01 2.20
15 0.14 0.70
24 (Tumor) 56.90 33.40
FIGURE 1. (A) Aflatoxin B,-DNA adduct levels as measuredby aflatoxin in-
hibition ELISA after immunoaffinity chromatography in normal and tumor
tissue from cancer patients and "control" colon tissue from autopsy from
autopsy samples. (B) Aflatoxin B,-DNA adduct levels as measured by inhibi-
tion ELISA following immunoaffinity chromatography in avariety oforgans
obtained at autopsy including samples from "exposed" individuals from
Southeast Asia.
Discussion
The detection ofAFB,-DNA adducts in all tissue types ex-
amined to date parallels the situation withpolyaromatic hydro-
carbon (PAH)-DNA adducts incigairette smokers.-Inthe caseof
smokers, adducts were detected in all tissues examined, which
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FIGURE 3. Aflatoxin B,-DNA adducts in normal and tumorous colon tissues from the same patient, as measured by inhibition ELISA after immunoaffinity
chromatography.
were alsoknown targetorgansforcigarette-inducedcancers. The
levels of PAH-DNA adducts detected were also strongly cor-
related with the number of cigarettes smoked in a lifetime
(45,46). Theliver, colon, pancreas, bileducts, andkidneyhave
all been shown to be target organs for AFBI-induced car-
cinogenesis inavariety ofanimals includingnonhumanprimates
(26,44,4748). Humancolonexplantshavealsobeenshowntobe
capable ofmetabolizing AFB, to produce DNA adducts (49),
and a variety ofhuman tissues are known to contain the P-450
isozyme thoughttoberesponsible forAFB1 activation (50; C. R.
Wolf, personalcommunication). ThelevelsofAFBI-DNAad-
ducts reportedhereare similartothosedetected inhumanliver
byourselvesandothers (14,40,51). Theseadductlevelsareofthe
sameorderofmagnitudeasthoseresulting in a40-50% tumor
incidence in rats and trout (38,53,53). Various reports indicate
thatthere is alinearrelationshipbetweenadductlevelandtumor
incidence inall speciesexamined. Thedetection ofAFB1-DNA
adducts in UKresidentstherefore maybeindicativeofpersistent
exposuretoAFB,, andthismaybecontributing tothecancerrisk
in a variety oforgans.
Thefactthattheadductsdetected (wheresamplesizeallowed)
havebeen shown tobethering-opened form indicatesthatthere
is a persistent, chronic exposure to aflatoxins in the UK. The
average adduct levels seen here cannot be accounted for solely
by the consumption ofknown sources ofaflatoxinexposure: If
AFBI metabolism in maninanywayparallels thatintherat, the
adduct levels seenwould represent anexposureof50pg/kg (52),
representing the consumption ofsome 350 kg ofpeanuts con-
taminated at 10ppb. Withtheaveragepercapitaconsumption of
peanuts intheUK at 1.5 kgperyear, thereclearly mustbeother
sources ofaflatoxin exposure.
Utilizing the relationship betweenAFBI-serumalbumin ad-
duct levels and organ DNA adduct levels (53) wehave already
begunaninvestigation astothepossible sourcesofaflatoxinex-
posure. By combining dietary questionnaires withthe analysis
ofAFB -serumalbumin adductlevelsandtheanalysisofawide
variety of foods from local shops, we hope to establish the
sources of the adduct levels reported here. We are also in
vestigating thepossibilityofendogenousaflatoxinproductionby
species ofAspergillus or other aflatoxin-producing fungi col-
onizingthegut, firstby establishing in an animal model ifsuch
colonization is possible and then by investigating urinary and
fecal total aflatoxin levels inpatients on normal, synthetic, and
fluid-only diets at the local hospital.
Infiveoutofeightcoloncancercases, theAFB1-DNAadduct
levels in tumor tissue were higher than levels in normal tissue
fromthe samepatient (adducts notbeing detected in two ofthe
patients andbeing equal inthethird). These results are consis-
tent with recent findings that show that the P-450 isozyme
responsible forAFB1 metabolism iselevatedincertainliverand
breast tumors, despite ageneral reduction ofoverall P-450 ac-
tivity in tumors (50; C. R. Wolf, personal communication).
The sensitivity ofdifferent species offish to AFBI induced
tumors hasbeenrelatedtothedifference intheirability to pro-
ducethereactiveepoxide(53). ThedetectionofAFB1-DNAad-
ducts in "normal" individuals and the lack ofadducts in some
cancerpatientsindicatesthateithera) someindividualslackthe
specific P450isozymes requiredtoproducetheepoxide; b)they
havehavehigh levels oftheglutathionetransferaseisozyme re-
quiredfordetoxififcation; c)theyhaveextremelyefficientrepair
systems;d)theyhaveneverbeenexposedtoAFB1 orhaveadduct
levelsbelowtheminimumdetection level ofthis system (30 pg
AFB1).
Inthelast30years, muchhasbeenlearnedabouttheaflatox-
insandtheirpossible roleincarcinogenesis. Theirpartinhuman
cancerdevelopment is still fiercely debated and requires further
investigation. Aflatoxinshavepredominantlybeenconsidereda
potential riskforPHC development, asthis istheprimary target
organ in the rat and because ofthe epidemiological links with
PHC and AFB1 exposure in the Third World. The results
presented here indicate that the aflatoxins may in fact be a risk
factor for cancerinduction in avariety oforgans inman, in the
same manner as that ofcigarette smoking. Other compounds,
suchasbenzidineand2-napthylamine, haveproducedtumors in
rats atquitedifferentsitestotheprimary targetinman, and such
mightbe the case with aflatoxins.
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